FDA warns Bonami Baking over insanitary conditions, pest and allergen risks in ready-to-eat bakery products.
What happened
FDA inspected the Bonami Baking facility in Pittsburg, CA, on April 4-22, 2022, and found serious violations of food-manufacturing practice, preventive-control, and labeling rules. Investigators observed rodent excreta on ingredient bags, live ants, gaps and holes in the facility, allergen cross-contact from inadequate cleaning, and no complete food safety plan. FDA received the company's response on May 5, 2022, but found it incomplete for several issues.
What FDA found
The firm did not have a food safety plan with required hazard analysis, preventive controls, supply-chain program, recall plan, monitoring, corrective action, or verification procedures.
21 CFR 117.126(a)(1)-(2), 117.130(a)(2), 117.135(b), 117.139(a), 117.145(a), 117.150(a)(1), 117.165(b)The firm did not identify allergens as a hazard requiring a preventive control and did not control allergen cross-contact on shared equipment and utensils.
21 CFR 117.130(a); 117.135(c)(2)The firm did not identify environmental pathogens such as Salmonella as a hazard for ready-to-eat products exposed after baking and lacked required environmental monitoring.
21 CFR 117.130(c)(1)(ii); 117.165(a)(3)The firm did not validate oven bake times and temperatures or check thermometer and timer accuracy to control bacterial pathogens such as E. coli and Salmonella in wheat flour.
21 CFR 117.160; 117.165(a)(1)The firm did not keep the plant clean and in repair or clean equipment safely, including using a non-food-contact chemical spray and drying equipment with a leaf blower near a dumpster.
21 CFR 117.35(a)The firm did not exclude pests, with rodent excreta on ingredient bags, live ants, and gaps and holes in the facility.
21 CFR 117.35(c)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the letter of specific steps taken to address the violations, with documentation and steps to prevent recurrence; if corrections cannot be completed in that time, the company must state why.
Who should pay attention
- retailers and foodservice operators selling ready-to-eat bakery products from this facility
- brands that buy baked goods from contract manufacturers
- consumers with food allergies
This is a summary. Read the original letter on fda.gov.